BDSX stock forecast, quote, news & analysis

Key Takeaways

• BDSX has fallen roughly 29% over the past 30 days, retreating from about $29.10 to near $20.79 after peaking at a 52-week high of $31.97 in late September.
• The pullback reflects profit-taking and a sharp valuation reset following a rapid multi-week advance, rather than a specific negative company announcement.
• Operating fundamentals held firm: Biodesix reaffirmed full-year 2026 revenue guidance of $108–$114 million and reported 34% year-over-year revenue growth in Q2 2026.
• Wall Street sentiment stayed constructive, with multiple analysts raising price targets into October and a consensus "Strong Buy" rating near a $39 average target.
• Over the trailing quarter, the stock round-tripped from the low $20s to near $32 and back, leaving it roughly flat versus three months ago.
• Get deeper context on this ticker by exploring its Price Targets, Earnings, and Forecast pages.
• Discover top-performing strategies on the Trending AI Robots page.

Biodesix (BDSX) Company Overview and Market Position

Biodesix, Inc. is a diagnostic solutions company focused on lung disease. Its flagship Nodify Lung platform — including the Nodify XL2 and Nodify CDT tests — uses blood-based proteomic analysis to help physicians assess whether suspicious lung nodules are more likely to be malignant or benign. The company also markets IQLung tests such as GeneStrat and VeriStrat, which guide treatment selection after a lung cancer diagnosis. Complementing its commercial tests, Biodesix Development Services provides test discovery, clinical-trial support, and companion diagnostics work for biopharmaceutical and life sciences partners.

Investors follow BDSX for its high-margin, recurring blood-test revenue model, its expansion beyond pulmonology into primary care, and its path toward sustained profitability. With gross margins near 80% and a growing pipeline spanning molecular residual disease (MRD) monitoring and digital diagnostics, Biodesix occupies a distinctive niche in early lung-cancer detection.

Biodesix (BDSX) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, BDSX has declined approximately 29%, falling from a close near $29.10 in late September to about $20.79 as of late October. The decline accelerated after the stock reached a 52-week high of $31.97 on September 28, with much of the selling concentrated in the final two weeks of the period.

The picture over the trailing quarter is more mixed. The stock began the period in the low $20s in late July, rallied roughly 45% into late September, and then gave back the entire advance. As a result, BDSX trades only modestly below where it stood roughly three months ago, underscoring how volatile the recent round-trip has been despite the sharp 30-day move.

What Drove BDSX Stock Price in the Last 30 Days

The steep late-September advance into a 52-week high was supported by a steady stream of positive developments. Analysts raised price targets through September and October — including TD Cowen to $40, H.C. Wainwright to $38, and Roth MKM to $41 — citing large addressable markets, rapid test-volume growth, and margin momentum. Biodesix also announced a partnership with Vanderbilt University to develop a radiomics-based digital diagnostics platform for lung nodule risk assessment, and multiple real-world studies supporting Nodify Lung testing were presented at CHEST 2026.

The subsequent decline, however, appears tied to technical and sentiment factors rather than any single piece of negative news. After such a rapid climb, the stock became vulnerable to profit-taking, and the reversal gathered momentum as the shares broke below recent support levels. Broader volatility in small-cap healthcare and diagnostics names compounded the move. Notably, no major company-specific setback coincided with the pullback — analyst ratings remained Buy-equivalent, and management reaffirmed its full-year outlook.

What Drove BDSX Stock Performance Over the Last Quarter

The broader three-month narrative was driven by accelerating adoption of the company's lung diagnostics tests. In Q2 2026, Biodesix delivered $26.9 million in revenue, up 34% year over year, alongside an 82% gross margin. Primary care test volume grew sharply, and the company continued expanding its sales force while extending Nodify CDT into smaller lung nodules.

Progress on the MRD front and the digital diagnostics collaboration added to the growth story and helped fuel the rally into late September. Yet the same catalysts that powered the climb also set up the reversal: with the stock priced for continued execution, even routine profit-taking triggered an outsized correction. The result is a quarter defined by a sharp rally followed by an equally sharp giveback.

Trending AI Robots

Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant strategies appear in its curated Trending AI Robots section. These bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term momentum signals to longer-horizon trend models. For traders seeking a data-driven way to filter opportunities, exploring these automated approaches can add a useful layer of perspective alongside fundamental research.

BDSX Stock Forecast Drivers: What Investors Should Watch Next

Several factors will shape the stock's direction in the coming weeks. Biodesix reports third-quarter 2026 results on November 5, 2026, making revenue growth, gross margin, and any update to full-year guidance the near-term focus. Investors will also watch reimbursement and payer-coverage developments for the Nodify tests, as well as the company's research-and-development update expected around the November AMP meeting, which may shed light on MRD and pipeline programs.

Broader considerations include the pace of primary care adoption, sales-force productivity, progress toward sustainable adjusted EBITDA and free-cash-flow break-even, and the level of cash burn. As with any small-cap diagnostics name, sector rotation and risk sentiment can amplify price swings regardless of underlying fundamentals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations